Spiroxazolidinone compounds

US8742110B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Joseph L. Duffy · Cranford, US
• Jianming Bao · Scotch Plains, US
• Debra L. Ondeyka · Fanwood, US
• Sriram Tyagarajan · Edison, US
• Patrick Shao · Fanwood, US
• Feng Ye · Scotch Plains, US
• Revathi Reddy Katipally · Monmouth Junction, US
• Aaron Zwicker · New Haven, US
• Edward C. Sherer · Manville, US
• Michael A. Plotkin · Frenchtown, US
• Remond Moningka · Jersey City, US
• Zahid Hussain · Monmouth Junction, US
• Harold B. Wood · Westfield, US
• Feroze Ujjainwalla · Hoboken, US
• F. Anthony Romero · South San Francisco, US
• Paul E. Finke · Milltown, US
• Yi Zang · Princeton Junction, US
• Weiguo Liu · San Leandro, US

Key dates

• Filing date: Aug 12, 2011
• Grant date: Jun 3, 2014
• Expiry date: Aug 12, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.